Elbit Medical is a holding company which was established in order to gather all of Elbit groups' bio medical and medical devices investments under one entity. By utilizing the advantages of a focused and professional management team, Elbit Medical intends to continue and expanded its investment in InSightec and Gamida Cell.
Our medical division includes investments in:
InSightec Ltd in which we hold a stake of 65.9%, is engaged in the development, production and marketing of magnetic resonance imaging guided ultrasound equipment.
Gamida Cell Ltd, in which we hold a stake of 31.6%, is engaged in the development of stem cell therapeutics based on its proprietary technologies for stem cell expansion as well as future regenerative cell-based medicines including heart tissue repair.
As of today Elbit Medical tradable its investments in its bio tech and medical field under the traded company Elbit Medical Technologies Ltd. (TASE: EMTC) for more details about the transaction please click here
InSightec Ltd. is a privately held company owned by Elbit group, General Electric, MediTech Advisors, LLC and employees. It was founded in 1999 to develop MR guided Focused Ultrasound technology and transform it into the next generation operating room.
ExAblate is the first system to use the breakthrough MRgFUS technology that combines MRI (used to visualize the body anatomy, plan the treatment and monitor treatment outcome in real time) and a high intensity focused ultrasound, to non-invasively, thermally ablate tumors inside the body.
MR thermometry is a unique system that allows the physician to control and adjust the treatment in real time to ensure that the targeted tumor is fully treated and surrounding tissue is spared.
Approved by the U.S. Food and Drug Administration in 2004 as a treatment for symptomatic uterine fibroids, ExAblate has been recognized for its innovation and potential to serve mankind and has been awarded the 2004 European Union's Information Society Technologies grand prize, The Wall Street Journal's 2004 Technology Innovation Awards, Advanced Imaging's 2005 Solutions of the Year, the Red Herring 100 Europe 2007 Award and the World Economic Forum Technology Pioneer 2008.
Headquartered near Haifa, Israel, with additional offices in the US, the company has over 160 employees and has invested in research, development, and clinical investigations.
For additional information please see InSightec’s web site: http://www.inSightec.com/
Gamida Cell Ltd.
Enhancing the Power of Stem Cell Therapy Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine.
The company’s pipeline of stem cell therapy products, derived from non-controversial sources such as umbilical cord blood, are in development to treat a wide range of conditions including blood cancers such as leukemia and lymphoma, autoimmune diseases, metabolic diseases and neutropenia.
StemEx® - Gamida Cell’s First Stem Cell Therapy Product The company’s lead stem cell therapy product, StemEx, is now being studied in an international, Phase III clinical trial as an alternative experimental treatment to a bone marrow transplant for blood cancer patients, who cannot find a matched related bone marrow donor. The StemEx study is enrolling patients at prestigious cord blood transplant centers in Israel, Italy, Hungary, Spain and throughout the U.S.
The market launch of the StemEx stem cell therapy product is planned for 2012. StemEx is designated as an orphan drug in the U.S. and Europe with 7-10 years market exclusivity, in addition to long term patent protection.It is also expected to be among the first allogeneic cell products to reach the market in 2011.
Apart from Elbit, Gamida Cell’s current shareholders also include Biomedical Investment, Israel Healthcare Venture, Teva Pharmaceutical Industries, Amgen, Denali Ventures and Auriga Ventures.
For additional information please see Gamida Cell’s web site: http://www.gamida-cell.com/